What is Boswellia serrata?
Boswellia serrata is a tree that produces an aromatic resin, sometimes known as Indian frankincense. Extracts of that resin contain a family of compounds called boswellic acids, which have attracted research interest in joint-health contexts.
Boswellia’s history is often used as proof in advertising, but traditional use and modern evidence are not the same thing. The relevant questions for a dog product are: what preparation is used, how consistent is it, what has been studied in dogs, and what claim can honestly be made?
FieldStrength Naturals includes Boswellia in Joint+ Collagen Paste, where it plays a supporting botanical role alongside collagen peptides, green-lipped mussel, rosehip, turmeric and oils.
Why extract quality matters
“Boswellia” is not one uniform substance. Species, resin source, extraction method and standardisation all influence the amount and balance of boswellic acids. Even the way those compounds are measured can produce variation between reports.
This matters because a study of one characterised extract does not automatically validate a different powder or blend. An impressive ingredient name on a label tells you less than many people assume.
Bioavailability is another issue. Individual boswellic acids do not all behave alike in the body, and canine pharmacokinetic work has shown that exposure can differ between compounds. Formulation and feeding conditions can influence what reaches circulation.
That is not a reason to reject the ingredient. It is a reason to reject certainty based on the name alone.
What does the canine evidence show?
Boswellia has been included in several canine studies, but it is frequently tested as part of a multi-ingredient product. For example, controlled research has examined combinations containing Boswellia alongside undenatured type II collagen or other joint-oriented ingredients. Some studies report improvement in selected mobility, pain-scoring or activity outcomes.
Those results apply to the tested combination. They cannot show that Boswellia alone caused the change, nor can they confirm that every Boswellia-containing product is equivalent.
A scoping review of canine and feline osteoarthritis supplements found considerable diversity in products and study methods. That makes head-to-head certainty difficult. Small sample sizes, different outcome tools, varying durations and commercial formulation differences all affect interpretation.
The measured conclusion is that Boswellia has promising canine relevance and a plausible supporting role, but the evidence base remains product-specific and often combination-based. It should not be advertised as a natural replacement for veterinary pain treatment.
What can we say responsibly?
For a complementary feed, Boswellia can be described as a botanical ingredient selected to support normal joint function and mobility within a wider formula. We can explain that boswellic acids are actively researched. We should not say the ingredient treats inflammation, relieves pain or controls arthritis.
That distinction protects more than regulatory wording. It helps an owner make a better decision. A dog that is lame or uncomfortable may need examination, imaging, weight management, rehabilitation or prescribed medicine. A supplement cannot identify the cause.
If a dog already receives medication, ask the vet before introducing Boswellia or another botanical blend. Published safety data in dogs are not as extensive as they are for conventional feed ingredients, and interactions are not always well characterised.
Why it belongs in a formula, not a fairy tale
Joint+ is built around hydrolysed bovine collagen peptides, with Boswellia acting as one of several complementary ingredients. Green-lipped mussel and salmon oil provide marine-derived lipids; rosehip and turmeric contribute different botanical compounds; linseed and coconut oils create the paste base and additional fatty-acid context.
No single ingredient carries the whole story. This is a deliberate advantage. The product’s purpose comes from the complete formulation and its consistent use, not from pretending that an ancient resin can perform modern miracles.
It also means results from a Boswellia-plus-UC-II study cannot be used as direct evidence for Joint+, because Joint+ uses hydrolysed bovine Types I and III collagen peptides rather than undenatured type II collagen. Similar-looking joint products may work on very different formulation principles.
Practical use and observation
Follow the labelled feeding amount and introduce the paste as directed. Do not double the amount in pursuit of a faster response. Botanical compounds can affect palatability and digestion, and more exposure is not automatically more useful.
Assess normal routines rather than staging unusual tests. Note how the dog rises, settles, turns, climbs familiar steps, completes usual walks and recovers after ordinary work. Weekly observations reduce the temptation to interpret every good or bad day as a supplement effect.
Keep exercise appropriate and consistent. Maintain a healthy body condition. Feed a complete diet. These fundamentals set the context in which any complementary feed operates.
Seek veterinary advice for sudden change, persistent stiffness, pain, swelling, altered gait, reduced appetite or behaviour change. Supplements should never delay investigation.
The practical takeaway
Boswellia serrata is a credible but frequently oversold botanical. Its boswellic acids are scientifically interesting, and canine combination studies support continued attention. At the same time, extract variability, bioavailability and study design make sweeping claims unjustified.
Within Joint+, Boswellia has a clear supporting role in a focused joint and connective-tissue formula. The honest promise is nutritional support for normal function—not treatment, pain relief or a substitute for veterinary care.
Explore every component on our Ingredients page, see the complete range in the shop, and read our FAQs.
Sources and further reading
- canine/feline supplement scoping review, https://www.mdpi.com/2076-2615/13/5/870
- canine Boswellia constituent study, https://link.springer.com/article/10.1186/s12917-019-2021-7
- randomised canine combination study, https://pmc.ncbi.nlm.nih.gov/articles/PMC11524509/
- multi-ingredient canine study, https://pmc.ncbi.nlm.nih.gov/articles/PMC8162585/
—